Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine-Reference-Cited by-同舟云学术

Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine

Published:2012-12-12 Issue:2 Volume:27 Page:217-226
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Shihab Fuad S.¹,Cibrik Diane²,Chan Laurence³,Kim Yu Seun⁴,Carmellini Mario⁵,Walker Rowan⁶,Zibari Gazi⁷,Pattison James⁸,Cornu-Artis Catherine⁹,Wang Zailong⁹,Tedesco-Silva Jr Helio¹⁰

Affiliation:

1. Division of Nephrology; University of Utah School of Medicine; Salt Lake City; UT; USA

2. Department of Internal Medicine; University of Michigan; Ann Arbor; MI; USA

3. Health Sciences Center; University of Colorado; Denver; CO; USA

4. Yonsei University College of Medicine Severance Hospital; Seoul; Korea

5. Department of Surgery and Bioengineering; University of Siena; Siena; Italy

6. The Royal Melbourne Hospital; Parkville; VIC; Australia

7. Louisiana State Health Sciences Center; Shreveport; LA; USA

8. Guy's and St Thomas's NHS Foundation Trust; London; UK

9. Novartis Pharma AG; Basel; Switzerland

10. Hospital do Rim e Hipertensão; São Paulo; Brazil

Publisher

Wiley

Subject

Transplantation

Reference16 articles.

1. SDZ RAD, a new ramekin derivative: pharmacologic properties in vitro and in vivo;Schuler;Transplantation,1997

2. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine;Schuurman;Transplantation,1997

3. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies;Vitko;Am J Transplant,2004

4. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness;Chan;Transplantation,2008

5. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients;Tedesco Silva;Am J Transplant,2010

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study;Transplantation;2023-06-20

2. Edema Associated With Everolimus de Novo;Transplantation Proceedings;2021-11

3. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients;Transplantation Reviews;2021-09

4. Effect of everolimus‐based drug regimens on CMV‐specific T‐cell functionality after renal transplantation: 12‐month ATHENA subcohort‐study results;European Journal of Immunology;2020-12-28

5. Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study;Expert Opinion on Drug Safety;2020-07-20